STOCK TITAN
  1. Home
  2. News
  3. XAIR

Beyond Air Inc - XAIR STOCK NEWS

Welcome to our dedicated news page for Beyond Air (Ticker: XAIR), a resource for investors and traders seeking the latest updates and insights on Beyond Air.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Beyond Air's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Beyond Air's position in the market.

News
Beyond Cancer™ Selected to Present Proffered Posters Discussing Data from the UNO Therapy Program at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Rhea-AI Summary
Beyond Cancer, Ltd. to present two proffered posters at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023. Intratumoral administration of Ultra High-Concentration Nitric Oxide (UNO) and Anti PD-1 treatment leads to high tumor regression rates and prolonged survival in tumor-bearing mice. Ultra-high concentration nitric oxide (UNO) enhances anti-CTLA-4 treatment activity and induces a durable anti-tumor response.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.9%
Tags
conferences
-
News
Beyond Air® To Participate in the Roth MKM 2023 Healthcare Opportunities Conference
Rhea-AI Summary
Beyond Air, Inc. to present at Roth MKM 2023 Healthcare Opportunities Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences
-
News
Beyond Cancer™ to Present Initial Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2023 SITC Annual Meeting
Rhea-AI Summary
Beyond Cancer, Ltd. will present data at the SITC Annual Meeting on their Phase 1 study of ultra-high concentration nitric oxide ablation in cutaneous and subcutaneous malignancies. The meeting is scheduled for November 3rd - 5th in San Diego, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.19%
Tags
conferences clinical trial
News
Beyond Air® Announces Publication of Positive New Preclinical Data for the Treatment of Autism Spectrum Disorder
Rhea-AI Summary
Beyond Air announces new data supporting the development of selective nNOS inhibitors for the treatment of Autism Spectrum Disorder (ASD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.83%
Tags
clinical trial
-
News
Beyond Air® and Getz Healthcare Enter Strategic Collaboration to Commercialize LungFit PH in Asia-Pacific Region
Rhea-AI Summary
Beyond Air partners with Getz Healthcare to commercialize LungFit PH device in key Asia-Pacific countries, expanding reach outside the US
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.63%
Tags
none
-
News
Beyond Air® To Participate in the 2023 Cantor Global Healthcare Conference
Rhea-AI Summary
Beyond Air to present at 2023 Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
conferences
News
Beyond Air® Reports Financial Results for First Quarter of Fiscal Year 2024
Rhea-AI Summary
Beyond Air, Inc. (NASDAQ: XAIR) announced financial results for its fiscal quarter ended June 30, 2023. They reported commercial sales for LungFit® PH, secured $40 million in debt financing, and reached an agreement with the FDA for a clinical study. They also expanded their pipeline with a pre-clinical program for the treatment of autism spectrum disorder.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
earnings
-
News
Beyond Air® Announces Positive Preclinical Data on Role of Nitric Oxide in Autism Spectrum Disorder (ASD)
Rhea-AI Summary
Beyond Air, Inc. announces the presentation of data at the 2023 ISN and ESN meetings in Portugal that support the development of selective nNOS inhibitors for the treatment of Autism Spectrum Disorder (ASD). The data show that inhibition of NO production may reverse ASD phenotypes and provide evidence that NO is a pathologic factor in autism. Beyond Air plans to advance their selective nNOS inhibitors into a first-in-human study in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.35%
Tags
clinical trial
-
News
Beyond Air® To Participate in BTIG’s 2023 Virtual Biotechnology Conference
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.02%
Tags
conferences
News
Beyond Air® Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast
Rhea-AI Summary
Beyond Air, Inc. (NASDAQ: XAIR) to Report Financial Results for First Fiscal Quarter Ended June 30, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.42%
Tags
earnings
Stock XAIR logo
Beyond Air Inc

Nasdaq:XAIR

XAIR Rankings

#4635 Ranked by Market Cap
#5085 Ranked by Stock Gains
N/A Ranked by Dividends

XAIR Stock Data

66.10M
29.66M
17.98%
20.64%
7.62%
Other Industrial Machinery Manufacturing
Manufacturing
Link
US
Garden City

About XAIR

Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company developing a revolutionary NO Generator and Delivery System, LungFit™, that uses NO generated from ambient air to deliver precise amounts of NO to the lungs of ventilated and non-ventilated patients for the potential treatment of a variety of pulmonary diseases. LungFit™ can generate up to 400 ppm of NO for delivery either continuously or for a fixed amount of time, and has the ability to either titrate dose on demand or maintain a constant dose. The Company is currently applying its therapeutic expertise to develop treatments for pulmonary hypertension in various settings, in addition to treatments for respiratory tract infections that are not effectively addressed with current standards of care. Beyond Air is currently advancing its innovative LungFit™ in clinical trials for the treatment of severe lung infections such as SARS-CoV-2 and nontuberculous mycobacteria (NTM). Additionally, Beyond Air is performing preclinical testing of the use of ultra-high concentrations of NO with a proprietary delivery system, separate from LungFit™, to target certain solid tumors.